Health ❯ Pharmacology

Drug Development

Clinical Trials Therapeutics Combination Therapy Repurposing Drugs Cancer Drugs Natural Compounds Investigational Drugs Opioid Receptors NSAIDs ATI2341 FDA Approval Alternative Treatments Clinical Research Cancer Treatments Drug Repurposing Synthetic Drugs Antibody-Drug Conjugates ABHD6 Inhibitors Appetite Stimulants Molecular Targeting Hormone Regulation Aldosterone Inhibitors Research and Development ALOX15 Expression Molecular Pharmacology Ambroxol Biased Signaling Central Nervous System Drugs Treatment Options PDE3 Inhibitors Chagas Disease Treatment Dosage Optimization Opioid Overdose Treatment Peptide Drugs Biologics Cellular Mechanisms Therapeutic Approaches Research Initiatives Experimental Drugs Targeted Therapies Antibiotics Zileuton Hormonal Treatments GLP-1 Drugs Drug Mechanisms Therapeutic Strategies Inhaled Medications Treatment Strategies Compound Screening Insecticides Clinical Phases Seizure Medications Anticancer Agents Small Molecules Clinical Guidelines Asthma Treatments Metabolic Health Carbohydrate-based Drugs Kinase Inhibitors Biological Agents Targeted Therapy Opioid Withdrawal Neurological Diseases Aptamer Technology Cyclophilin Inhibitors Antifungal Drugs Molecular Design Natural Remedies Cannabinoids Anti-inflammatory Drugs KDS12025 Racetam Class Rapamycin Antidepressants Cancer Therapies Anticancer Drugs Anticoagulants Steroids Antiviral Agents Addiction Treatment Small-Molecule Drugs Cholesterol Drugs Enzyme Inhibitors Nucleoside Reverse Transcriptase Inhibitors G Protein-Coupled Receptors Topical Treatments Anti-inflammatory Agents Naloxone Enhancement Taste Receptors GSM-15606 Gene Therapy Biosensors GLP-1 Receptor Agonists

Enzyme Platform Produces Promising, Less-Toxic Polyene Candidate Nys34

Researchers used genome mining with enzyme-guided sugar addition and amidation to make polyenes more soluble and potent.

Scientists Find Small Molecules That Directly Inhibit β‑Arrestins

Lorundrostat Produces Blood-Pressure and Albuminuria Drops in Company Post Hoc Phase 3 Analysis

NIH Identifies DFNZ, a Nitazene Opioid That Eased Pain in Rats Without Breathing Risks

Tirzepatide Cuts Alcohol Drinking and Relapse-Like Behavior in Rodent Study

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Asundexian Cuts Recurrent Stroke 26% Without More Major Bleeding in Phase III

CXCR4 Circadian Checkpoint Puts Neutrophils in Night Mode, Reducing Cardiac Injury in Mice

Study Finds CBD–THC Combination Kills Ovarian Cancer Cells in Lab

Low-Dose Colchicine Lowers Heart Attack and Stroke Risk in Heart Disease, Cochrane Review Finds

New Review Positions Camelid Nanobodies as a Promising Path for Brain Therapies

Nature Study Shows Intracellular GPCR Targeting Can Direct Signaling

HSF1-Driven Autophagy Found to Undercut Proteasome Drugs in AML, Preclinical Combo Shows Benefit

Study Pinpoints EP2 Receptor in Schwann Cells as Target for Pain Relief Without Blocking Inflammation

CDC Journal Review Presses U.S. to Treat Chagas as Endemic

Semaglutide Curbs Cocaine Use and Relapse-Seeking in Rats, Peer-Reviewed Study Finds

Baxdrostat Lowers Blood Pressure in Hard-to-Treat Patients in Phase III Trial

Brain Hemoglobin Identified as an Antioxidant Target as Oral Molecule Protects Mice Across Disease Models

Bezafibrate Restores Blood–Brain Barrier Function in 22q11.2 Models, Study Finds

Autism-Like Behaviors in Mice Traced to Thalamic Circuit as Epilepsy Drug Candidate Reverses Signs